Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.

ESMO Open · 2026 · PMC12870864 · PMID 41610691

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Higher baseline percentages of CD3+CD8+ cytotoxic T lymphocytes or CD4+CD25+CD127− regulatory T cells showed a trend toward improved ORR.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.